Literature DB >> 28766084

Comparison of the EQ-5D-3L and the SF-6D (SF-12) contemporaneous utility scores in patients with cardiovascular disease.

Sanjeewa Kularatna1, Joshua Byrnes2,3, Yih Kai Chan4, Chantal F Ski4, Melinda Carrington4, David Thompson4, Simon Stewart4, Paul A Scuffham2,3.   

Abstract

PURPOSE: Multi-attribute utility instruments (MAUIs) are widely used to measure utility weights. This study sought to compare utility weights of two popular MAUIs, the EQ-5D-3L and the SF-6D, and inform researchers in the selection of generic MAUI for use with cardiovascular (CVD) patients.
METHODS: Data were collected in the Young@Heart study, a randomised controlled trial of a nurse-led multidisciplinary home-based intervention compared to standard usual care. Participants (n = 598) completed the EQ-5D-3L and the SF-12v2, from which the SF-6D can be constructed, at baseline and at 24-month follow-up. This study examined discrimination, responsiveness, correlation and differences across the two instruments.
RESULTS: Both MAUIs were able to discriminate between the NYHA severity classes and recorded similar changes between the two time points although only SF-6D differences were significant. Correlations between the dimensions of the two MAUIs were low. There were significant differences between the two instruments in mild conditions but they were similar in severe conditions. Substantial ceiling and floor effects were observed.
CONCLUSIONS: Our findings indicate that the EQ-5D and the SF-6D cover different spaces in health due to their classification systems. Both measures were capable of discriminating between severity groups and responsive to quality of life changes in the follow-up. It is recommended to use the EQ-5D-3L in severe and the SF-6D in mild CVD conditions.

Entities:  

Keywords:  EQ-5D; QALY; SF-6D; Utility

Mesh:

Year:  2017        PMID: 28766084     DOI: 10.1007/s11136-017-1666-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  26 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

Review 2.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

3.  Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients.

Authors:  David Feeny; Karen Spritzer; Ron D Hays; Honghu Liu; Theodore G Ganiats; Robert M Kaplan; Mari Palta; Dennis G Fryback
Journal:  Med Decis Making       Date:  2011-10-18       Impact factor: 2.583

4.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

5.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

6.  The Declaration of Helsinki and public health.

Authors:  John R Williams
Journal:  Bull World Health Organ       Date:  2008-08       Impact factor: 9.408

7.  Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.

Authors:  Donna Rowen; Tracey Young; John Brazier; Sabine Gaugris
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

8.  A multicenter, randomized trial of a nurse-led, home-based intervention for optimal secondary cardiac prevention suggests some benefits for men but not for women: the Young at Heart study.

Authors:  Melinda J Carrington; Yih-Kai Chan; Alicia Calderone; Paul A Scuffham; Adrian Esterman; Stan Goldstein; Simon Stewart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07-02

9.  A comparison of the EQ-5D and SF-6D across seven patient groups.

Authors:  John Brazier; Jennifer Roberts; Aki Tsuchiya; Jan Busschbach
Journal:  Health Econ       Date:  2004-09       Impact factor: 3.046

10.  The impact of adding an extra dimension to a preference-based measure.

Authors:  John Brazier; Donna Rowen; Aki Tsuchiya; Yaling Yang; Tracy A Young
Journal:  Soc Sci Med       Date:  2011-06-02       Impact factor: 4.634

View more
  8 in total

Review 1.  How is quality of life defined and assessed in published research?

Authors:  Daniel S J Costa; Rebecca Mercieca-Bebber; Claudia Rutherford; Margaret-Ann Tait; Madeleine T King
Journal:  Qual Life Res       Date:  2021-04-01       Impact factor: 4.147

2.  Comparison between the EQ-5D-3L and the SF-6D quality of life (QOL) questionnaires in patients with chronic obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery (LVRS).

Authors:  Sowmyanarayanan Thuppal; Stephen Markwell; Traves Crabtree; Stephen Hazelrigg
Journal:  Qual Life Res       Date:  2019-02-01       Impact factor: 4.147

3.  Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.

Authors:  Sanjeewa Kularatna; Sameera Senanayake; Nalika Gunawardena; Nicholas Graves
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

4.  Correlation of the disease-specific Canadian Cardiovascular Society (CCS) classification and health-related quality of life (15D) in coronary artery disease patients.

Authors:  Jarno Kotajärvi; Anna-Maija Tolppanen; Juha Hartikainen; Heikki Miettinen; Marketta Viljakainen; Janne Martikainen; Risto P Roine; Piia Lavikainen
Journal:  PLoS One       Date:  2022-04-01       Impact factor: 3.240

5.  Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.

Authors:  Shitong Xie; Dingyao Wang; Jing Wu; Chunyu Liu; Wenchen Jiang
Journal:  Health Qual Life Outcomes       Date:  2022-06-16       Impact factor: 3.077

6.  Translation, Cross-Cultural Adaptation, and Psychometric Testing of Yoruba Version of the EQ-5D Questionnaire in Patients With Musculoskeletal Disorders.

Authors:  Francis Fatoye; Abiodun Emmanuel Akinfala; Tadesse Gebrye; Clara Fatoye; Titilope Faith Ojelade; Olufemi Oyeleye Oyewole; Chidozie Emmanuel Mbada
Journal:  Front Public Health       Date:  2022-06-27

7.  The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial.

Authors:  Hasnain M Dalal; Rod S Taylor; Kate Jolly; Russell C Davis; Patrick Doherty; Jackie Miles; Robin van Lingen; Fiona C Warren; Colin Green; Jennifer Wingham; Colin Greaves; Susannah Sadler; Melvyn Hillsdon; Charles Abraham; Nicky Britten; Julia Frost; Sally Singh; Christopher Hayward; Victoria Eyre; Kevin Paul; Chim C Lang; Karen Smith
Journal:  Eur J Prev Cardiol       Date:  2018-10-10       Impact factor: 7.804

8.  Correspondence to European Heart Journal-Quality of Care and Clinical Outcomes in response to paper by Thomas, M. et al. 2021: Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failures.

Authors:  Hasnain Dalal; Rod S Taylor; John G Cleland
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-07-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.